Gazyva (obinutuzumab) / Roche, Biogen 
Welcome,         Profile    Billing    Logout  
 23 Diseases   163 Trials   163 Trials   4765 News 


«12...2122232425262728293031...6061»
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Increase in Antibody Titers Following Sars-Cov-2 Vaccination Remains Limited for More Than 3 Years after Final Dose of Anti-CD20 Antibody (GWCC - Thomas Murphy Ballroom 3-4, Level 5) -  Nov 5, 2021 - Abstract #ASH2021ASH_1969;    
    We first evaluated antibody titers in 12 healthy volunteers (median age 75.5 years, range 57–82) and three lymphoma patients undergoing R-CHOP therapy (73, 81, and 81 years old) who had received 2 vaccine doses of BNT162b2 at pre-vaccination, 21 days after the first dose and 14 days after the second dose of vaccination...Thirty-four patients had received rituximab-based and 2 had received obinutuzumab-based therapy, with a median of 6 (range 3–20) courses...Alternative protection strategies for these patients are therefore warranted. Although T-cell responses were detected, we recommend that these patients continue to wear a face mask and wash their hands to prevent COVID-19 even after vaccination.
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis
    Tisagenlecleucel Demonstrates Safety, Efficacy and CNS Trafficking in Primary CNS Lymphoma (GWCC - Hall A1) -  Nov 5, 2021 - Abstract #ASH2021ASH_1569;    
    P1
    The majority of patients demonstrated a response per IPCG, including responses beyond 12 months. Tisagenlecleucel was found to expand in the peripheral blood and CNS with CSF gene signatures suggestive of higher CAR-T cell infiltrates in responding patients.
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen, Zelboraf (vemurafenib) / Roche
    First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl (GWCC - A411-A412, Level 4) -  Nov 5, 2021 - Abstract #ASH2021ASH_1252;    
    P2
    Most pts had normalization of cytopenia after a 4-week lead-in of vemurafenib with no case of febrile neutropenia and no evidence of significant T cell immunosuppression on therapy. While we have not observed any relapse to date, a longer follow-up is needed to assess durability of remission compared to purine nucleoside-treated cohorts.
  • ||||||||||  rhIL-15 / National Cancer Institute
    Enrollment closed:  Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia (clinicaltrials.gov) -  Nov 4, 2021   
    P1,  N=1, Active, not recruiting, 
    Patients in the EZH2_mut cluster had significantly longer PFS with CHOP/CVP-based regimens (HR = 4.99, P = 0.002), while the EZH2 GEP signature was not predictive in patients receiving Bendamustine-based treatment ( Fig B ). Suspended --> Active, not recruiting
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen
    Clinical, Review, Journal:  Pancreatic follicular lymphoma: a report of two cases and literature review. (Pubmed Central) -  Nov 4, 2021   
    Both achieved complete response with induction therapy and opted for maintenance therapy with obinutuzumab. We also conducted a literature review of primary pancreatic follicular lymphoma cases reported over the last 30 years.
  • ||||||||||  Arzerra (ofatumumab) / Novartis, Genmab
    Journal:  The selection of variable regions affects effector mechanisms of IgA antibodies against CD20. (Pubmed Central) -  Nov 4, 2021   
    These data characterize the functional activities of human IgA2 antibodies against CD20, which were affected by the selection of the respective variable regions. OBI-IgA2 proved particularly effective in vitro and in vivo, which is potentially relevant in the context of CD47-SIRPα blockade.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Calquence (acalabrutinib) / AstraZeneca
    Clinical, P2 data, Journal:  Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. (Pubmed Central) -  Nov 4, 2021   
    P2, P3
    Acalabrutinib, venetoclax, and obinutuzumab is a highly active and well tolerated frontline therapy for chronic lymphocytic leukaemia. Although the primary endpoint of this study was not met, the high proportion of patients who had undetectable MRD in the bone marrow supports further investigation of this regimen, which is being tested against acalabrutinib-venetoclax and chemoimmunotherapy in an ongoing phase 3 study (NCT03836261).
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
    Trial completion date:  NOBILITY: A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN) (clinicaltrials.gov) -  Nov 2, 2021   
    P2,  N=126, Active, not recruiting, 
    Although the primary endpoint of this study was not met, the high proportion of patients who had undetectable MRD in the bone marrow supports further investigation of this regimen, which is being tested against acalabrutinib-venetoclax and chemoimmunotherapy in an ongoing phase 3 study (NCT03836261). Trial completion date: Nov 2021 --> Jun 2022
  • ||||||||||  Benlysta (belimumab) / GSK, Luveniq (voclosporin) / Aurinia Pharma, Otsuka, Gazyva (obinutuzumab) / Roche, Biogen
    Review, Journal:  The treatment of lupus nephritis, between consolidated strategies and new therapeutic options: a narrative review (Pubmed Central) -  Oct 27, 2021   
    Recently published (or nearing completion) studies have opened up the possibility of using new drugs in LN. In particular, depletion (Obinutuzumab, anti-CD20 monoclonal antibody) or neutralization (Belimumab, anti-"B-cell activating factor" monoclonal antibody) of B lymphocytes, and the use of a calcineurin inhibitor with a low profile of renal and systemic toxicity (Voclosporin) demonstrated an improvement in renal response in addition to standard therapy.
  • ||||||||||  Benlysta (belimumab) / GSK, Luveniq (voclosporin) / Aurinia Pharma, Otsuka
    Clinical, Journal:  B-cell depletion or belimumab or voclosporin for lupus nephritis? (Pubmed Central) -  Oct 22, 2021   
    These studies will change the treatment landscape of lupus nephritis. In which way is discussed in this article.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Journal, PD(L)-1 Biomarker, IO biomarker:  Immune checkpoint markers and anti-CD20-mediated NK cell activation. (Pubmed Central) -  Oct 22, 2021   
    Blockade of TIGIT, TIM3, or both had little impact on RTX-induced NK cell proliferation, degranulation, cytokine production, or activation. Taken together, TIGIT and TIM3 can serve as markers for anti-CD20-mediated NK cell activation, but may not serve well as targets for enhancing the anti-tumor activity of such therapy.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Granulomatous Interstitial Nephritis Secondary to Chronic Lymphocytic Leukemia () -  Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_1402;    
    Our patient had partial renal recovery with steroids, obinutuzumab, and venetoclax indicating the efficacy of this regimen compared to rituximab, cyclophosphamide, and steroids. Our case highlights a rare entity of GIN that maybe underdiagnosed in patients with CLL.
  • ||||||||||  Vistide (cidofovir) / Gilead
    [VIRTUAL] BK Polyomavirus Nephritis in a Low-Risk Native Kidney: A Case Report () -  Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_1011;    
    This case highlights that BK nephropathy may develop in the native kidney other than HSCT. Chronic lymphopenia & hypogammaglobinemia likely predisposed our patient despite his ongoing infusion of IVIG.
  • ||||||||||  Pixuvri (pixantrone) / Servier, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
    Trial completion date, Combination therapy:  GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma (clinicaltrials.gov) -  Oct 14, 2021   
    P2,  N=70, Active, not recruiting, 
    When considering cost, effectiveness, and toxicities, the preferred treatment strategy for most patients with POD24 follicular lymphoma is ASCT. Trial completion date: Jun 2022 --> Dec 2021